相关实验视频
Updated: Mar 13, 2026
08:31
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
11.6K
动态的葡萄糖反应性半孔二氧化纳米颗粒涂层,用于双模式药物输送的轨道植入物
Shiqing Ma1, Mengzhen Cui2,3, Kexin Chang2,3
1Department of Stomatology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
Materials today. Bio
|March 12, 2026
概括
这项研究介绍了一种针对糖尿病的智能植入物,它根据血糖水平动态释放阿司匹林. 它可以改善骨愈合,并减少糖尿病患者的炎症.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 纳米技术纳米技术
背景情况:
- 糖尿病会损害植入体的整合,原因是骨形成不良和慢性炎症.
- 波动的血糖水平使治疗过程复杂化,使静态药物释放对糖尿病患者无效.
研究的目的:
- 开发一种对葡萄糖敏感的植入系统,以增强糖尿病患者的骨质整合.
- 创建一个智能生物材料,可以动态传递阿司匹林,以解决骨质生成和炎症的损伤.
主要方法:
- 制造了一种被酸修饰的半孔纳米颗粒覆盖的晶体植入物,装载着阿司匹林.
- 开发一种可响应葡萄糖水平的双模式药物输送系统 (常态血糖与高血糖).
- 在体外评估干细胞骨质分化和巨细胞分化;在糖尿病老鼠骨缺陷模型中的体内评估.
主要成果:
- 植入物展示了动态的,对葡萄糖反应的阿司匹林释放,在正常血糖症下缓慢释放,在高血糖症下加速释放.
- 试验室研究显示,骨质分化的增强和M2巨细胞的两极分化.
- 该系统显著改善了糖尿病老鼠模型中的骨质整合和减少炎症反应.
结论:
- 成功开发了一种代谢适应的植入物表面,将状与对葡萄糖敏感的纳米载体集成在一起.
- 这一策略有效地解决了骨质生成受损和糖尿病炎症的双重挑战,通过将药物释放与代谢状态相结合.
- 开发的智能生物材料在治疗需要植入植入的糖尿病患者的临床转化方面显示出前景.
相关概念视频
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
01:24Modified-Release Drug Delivery Systems: Site-Targeted
70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70
01:18Transdermal Drug Delivery Systems
87
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
87
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
73
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
73
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
66
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
66
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
76
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
76